N
KROS icon

Natixis’s Keros Therapeutics KROS Stock Holding History

Natixis’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$1.1K – 1279
2026
Q1 		$1.1K Buy
+100
New +$1.54K ﹤0.01% 1063

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Natixis's KROS Position: Q2 2026 in Review

Natixis sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 100 shares — an estimated $1.1K sold.

Natixis first reported a position in KROS in Q1 2026 and held it in 1 quarter. The position peaked at $1.1K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Natixis reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 100 Keros Therapeutics shares in Q2 2026, an estimated $1.1K.
  • Natixis first reported a position in Keros Therapeutics in Q1 2026 and held it in 1 quarter.
  • Natixis's Keros Therapeutics position peaked at $1.1K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.